Page last updated: 2024-11-02

pioglitazone and Experimental Hepatoma

pioglitazone has been researched along with Experimental Hepatoma in 2 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Guo, YT1
Leng, XS1
Zhao, JM1
Lin, XH1
Li, T1
Zhu, JY1
Solomon, SS1
Mishra, SK1
Cwik, C1
Rajanna, B1
Postlethwaite, AE1

Other Studies

2 other studies available for pioglitazone and Experimental Hepatoma

ArticleYear
[Pexoxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2005, Volume: 13, Issue:2

    Topics: Animals; Antineoplastic Agents; Chromans; Diethylnitrosamine; Ligands; Liver Neoplasms, Experimental

2005
Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1997, Volume: 29, Issue:8

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance;

1997